PL3973987T3 - Kombinacja zawierająca antagonistę IL-4R, kortykosteroid i długo działającego agonistę beta2-adrenergicznego do leczenia astmy - Google Patents

Kombinacja zawierająca antagonistę IL-4R, kortykosteroid i długo działającego agonistę beta2-adrenergicznego do leczenia astmy

Info

Publication number
PL3973987T3
PL3973987T3 PL21191120.1T PL21191120T PL3973987T3 PL 3973987 T3 PL3973987 T3 PL 3973987T3 PL 21191120 T PL21191120 T PL 21191120T PL 3973987 T3 PL3973987 T3 PL 3973987T3
Authority
PL
Poland
Prior art keywords
corticosteroid
antagonist
combination
long
adrenergic agonist
Prior art date
Application number
PL21191120.1T
Other languages
English (en)
Inventor
Gianluca Pirozzi
Franck SKOBIERANDA
Yongtao Li
Neil Graham
Steven P. Weinstein
Original Assignee
Sanofi Biotechnology
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51570453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3973987(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc. filed Critical Sanofi Biotechnology
Publication of PL3973987T3 publication Critical patent/PL3973987T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21191120.1T 2014-02-21 2015-02-20 Kombinacja zawierająca antagonistę IL-4R, kortykosteroid i długo działającego agonistę beta2-adrenergicznego do leczenia astmy PL3973987T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
EP14306413 2014-09-15
US201462077669P 2014-11-10 2014-11-10

Publications (1)

Publication Number Publication Date
PL3973987T3 true PL3973987T3 (pl) 2024-06-24

Family

ID=51570453

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15708991T PL3107575T3 (pl) 2014-02-21 2015-02-20 Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
PL21191120.1T PL3973987T3 (pl) 2014-02-21 2015-02-20 Kombinacja zawierająca antagonistę IL-4R, kortykosteroid i długo działającego agonistę beta2-adrenergicznego do leczenia astmy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15708991T PL3107575T3 (pl) 2014-02-21 2015-02-20 Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R

Country Status (15)

Country Link
US (3) US10137193B2 (pl)
EP (3) EP4382164A3 (pl)
JP (3) JP6673840B2 (pl)
KR (4) KR20220029765A (pl)
CN (1) CN106232140A (pl)
AU (3) AU2015218808B2 (pl)
CA (1) CA2940295A1 (pl)
ES (2) ES2897631T3 (pl)
HU (1) HUE065844T2 (pl)
IL (1) IL315136A (pl)
MX (2) MX384192B (pl)
PL (2) PL3107575T3 (pl)
PT (2) PT3107575T (pl)
RU (1) RU2713406C2 (pl)
WO (1) WO2015127229A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
EP3010539B1 (en) 2013-06-21 2019-07-24 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3110848B1 (en) 2014-02-28 2024-02-14 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
JP6861630B2 (ja) 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
CN118141914A (zh) * 2016-09-01 2024-06-07 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
KR20190053250A (ko) 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI857389B (zh) * 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3957752B1 (en) 2017-04-13 2025-08-20 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
WO2019005898A1 (en) 2017-06-27 2019-01-03 Ohio State Innovation Foundation LIPONUCLEOTID THERAPY FOR COPD
EP3645010A4 (en) * 2017-06-27 2021-03-24 Ohio State Innovation Foundation NUCLEOTIDE-BASED THERAPY FOR ASTHMA
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
EP4344706A3 (en) * 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
TWI838388B (zh) * 2018-07-10 2024-04-11 美商雷傑納榮製藥公司 修飾結合分子以最小化已存在的交互作用
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
MY209489A (en) * 2018-12-27 2025-07-12 Akeso Biopharma Inc Antibody against human il-4ra and use thereof
WO2020191346A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3962515A1 (en) * 2019-05-01 2022-03-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
EP3999114A1 (en) * 2019-07-16 2022-05-25 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4010001A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
AU2020399975A1 (en) * 2019-12-09 2022-07-28 Sanofi Biotechnology Methods for treating digitally-identified IL-4/IL-13 related disorders
MX2023001140A (es) * 2020-08-05 2023-05-18 Areteia Therapeutics Inc Uso del dexpramipexol para el tratamiento de asma moderado a grave.
US20220169739A1 (en) * 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
TW202313692A (zh) * 2021-08-26 2023-04-01 大陸商正大天晴藥業集團股份有限公司 抗ｉｌ４ｒ抗體的藥物組成物及其用途
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
MXPA02011682A (es) 2000-05-26 2003-05-14 Immunex Corp Uso de antagonistas de interleuquina-4 y composiciones de los mismos.
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
ATE395358T1 (de) 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Ltd ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
PL2069403T3 (pl) 2006-10-02 2015-08-31 Regeneron Pharma Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2245064B1 (en) * 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
US20120004205A1 (en) 2008-12-01 2012-01-05 Cincinnati Children's Hospital Medical Center Il-13 induced gene signature for eosinophilic esophagitis
WO2010120524A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
AU2011312191B2 (en) 2010-10-06 2015-07-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
HUE034005T2 (en) * 2010-10-15 2018-01-29 Medimmune Ltd Therapies for improving lung function
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
ES2981062T3 (es) 2012-09-07 2024-10-07 Regeneron Pharma Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
EP3010539B1 (en) 2013-06-21 2019-07-24 Sanofi Biotechnology Methods for treating nasal polyposis by administering an il-4r antagonist
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
JP6861630B2 (ja) 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
EP4344706A3 (en) * 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US20220169739A1 (en) 2020-10-05 2022-06-02 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Also Published As

Publication number Publication date
AU2020277191B2 (en) 2024-05-16
CN106232140A (zh) 2016-12-14
KR20160113733A (ko) 2016-09-30
MX2016010854A (es) 2017-01-05
JP2023162343A (ja) 2023-11-08
PT3107575T (pt) 2021-11-18
AU2015218808B2 (en) 2020-09-24
ES2897631T3 (es) 2022-03-02
US20190125865A1 (en) 2019-05-02
WO2015127229A1 (en) 2015-08-27
HUE065844T2 (hu) 2024-06-28
EP4382164A2 (en) 2024-06-12
EP3973987B1 (en) 2024-01-10
RU2016136364A (ru) 2018-03-22
KR102368450B1 (ko) 2022-02-28
EP3107575B1 (en) 2021-09-01
US20210322546A1 (en) 2021-10-21
RU2016136364A3 (pl) 2018-10-11
AU2015218808A1 (en) 2016-09-22
CA2940295A1 (en) 2015-08-27
ES2977332T3 (es) 2024-08-22
US20150246119A1 (en) 2015-09-03
JP2017507139A (ja) 2017-03-16
EP4382164A3 (en) 2024-08-07
US10137193B2 (en) 2018-11-27
JP2025072593A (ja) 2025-05-09
MX384192B (es) 2025-03-14
RU2713406C2 (ru) 2020-02-05
AU2020277191A1 (en) 2020-12-24
KR20250154567A (ko) 2025-10-28
JP6673840B2 (ja) 2020-03-25
PL3107575T3 (pl) 2022-01-17
PT3973987T (pt) 2024-04-01
KR20230167770A (ko) 2023-12-11
IL315136A (en) 2024-10-01
JP7636487B2 (ja) 2025-02-26
MX2021008113A (es) 2021-10-13
KR20220029765A (ko) 2022-03-08
EP3973987A1 (en) 2022-03-30
AU2024203849A1 (en) 2024-06-27
EP3107575A1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
PL3973987T3 (pl) Kombinacja zawierająca antagonistę IL-4R, kortykosteroid i długo działającego agonistę beta2-adrenergicznego do leczenia astmy
PL3703818T3 (pl) Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
IL275257B (en) Method, Device, and Computer Software Product for Selecting a Packet Loss Concealment Process
SG10201406574SA (en) Reservation management method, computer program, and reservation management apparatus
EP3137918A4 (en) Positioning arrangement, method, mobile device and computer program
GB201510610D0 (en) Method, device, and computer program
EP3205379A4 (en) Skill determination program, skill determination method, skill determination device, and server
GB201420649D0 (en) Apparatus and methods for monitoring aerosol delivery
SG10201406577PA (en) Method, apparatus, and program
EP3200489A4 (en) Method and device for indicating bit number
EP3122144B8 (en) Device and method for accessing wireless network
PL3201842T3 (pl) Dokument elektroniczny z pochylonymi końcami anteny, obsługa anteny dla takiego dokumentu elektronicznego i sposób wytwarzania takiego dokumentu
EP3145206A4 (en) Communication apparatus, communication method, and computer program
EP3239741A4 (en) State calculating apparatus, state calculating method and state calculating program
GB2539120B (en) Apparatus, systems and methods for oil and gas operations
EP3163324A4 (en) Positioning device, positioning method, and program
SG11201508210YA (en) Partial discharge measurement device, partial discharge measurement method, and program
GB201505042D0 (en) Methods and apparatus for cutting a substrate
SG11201705274SA (en) Methods and apparatuses for form operation on a mobile terminal
GB201511378D0 (en) Apparatus, method and computer program
GB201511379D0 (en) Apparatus, method and computer program
EP3145207A4 (en) Communication apparatus, communication method, and computer program
EP3155734A4 (en) Method, apparatus and computer program
PL3151812T3 (pl) Cząstki do inhalacji obejmujące skojarzenie środka antycholinergicznego, kortykosteroidu i środka beta-adrenergicznego
EP3197000A4 (en) Management device, management method, and program